7440-66-6
CAS 7440-66-6
7440-66-6 (CAS 7440-66-6) is a pharmaceutical compound with 1 bioactivity target and 3,824 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | IC50 | 15000 nM | 1 | - |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| ZINC | 11416 | SU | MTHSPL |
| Zinc | 11416 | SU | MTHSPL |
| zinc | 11416 | SU | MTHSPL |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is 7440-66-6 used for in pharmaceutical contexts?
7440-66-6 (CAS 7440-66-6) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for 7440-66-6?
7440-66-6 has 3,824 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Abdominal abscess, Abdominal discomfort, Abdominal distension, Abdominal hernia, Abdominal mass. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is 7440-66-6 also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for ZINC with EU status "permitted".
What clinical phase is 7440-66-6 in?
No phase 1-4 clinical development badge is rendered for 7440-66-6 because the matched compound identifier rows do not contain a max-phase value.